Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.11363
Abstract: Key Points Question What is the prevalence and comparative effectiveness associated with buprenorphine and naltrexone in individuals with opioid use disorder (OUD) and cooccurring substance use disorders (SUDs)? Findings This comparative effectiveness study evaluated 179 280… read more here.
Keywords: buprenorphine; effectiveness associated; use; comparative effectiveness ... See more keywords
Naloxone and Naltrexone
Sign Up to like & getrecommendations! Published in 2019 at "Pain"
DOI: 10.1007/978-3-319-99124-5_66
Abstract: Naloxone is a highly specific, high-affinity opioid antagonist used to reverse the effects of opioids. It is available in several formulations for convenient administration by medical trained personnel and by lay persons in the ambulatory… read more here.
Keywords: naloxone naltrexone; naltrexone;
Naltrexone faible dose dans la maladie de Hailey–Hailey sévère, retour d’expérience sur 3 cas
Sign Up to like & getrecommendations! Published in 2019 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2019.09.547
Abstract: Introduction La maladie de Hailey–Hailey est une maladie autosomique dominante, secondaire a une mutation d’un transporteur de calcium, caracterisee par un trouble de l’adhesion keratinocytaire avec acantholyse. Nous rapportons trois cas particulierement severes et traites… read more here.
Keywords: maladie hailey; naltrexone; hailey; faible dose ... See more keywords
Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.
Sign Up to like & getrecommendations! Published in 2019 at "Drug and alcohol dependence"
DOI: 10.1016/j.drugalcdep.2019.02.028
Abstract: BACKGROUND Despite known genetic variation across races, studies examining pharmacogenetics of a single nucleotide polymorphism (SNP) of the mu-opioid receptor gene (OPRM1) on clinical response to naltrexone have been conducted in predominantly Caucasian samples. Evidence… read more here.
Keywords: heavy drinkers; east asian; taste cues; drinkers east ... See more keywords
Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex – United States, March 2019 – December 2020
Sign Up to like & getrecommendations! Published in 2021 at "Drug and Alcohol Dependence"
DOI: 10.1016/j.drugalcdep.2021.109192
Abstract: Background COVID-19 stay-at-home orders may reduce access to substance use treatment and naloxone, an opioid overdose reversal drug. The objective of this analysis was to compare monthly trends in pharmacy-based dispensing rates of medications for… read more here.
Keywords: naloxone; naltrexone; 2019 december; december 2020 ... See more keywords
Accelerated in vitro release testing method for naltrexone loaded PLGA microspheres.
Sign Up to like & getrecommendations! Published in 2017 at "International journal of pharmaceutics"
DOI: 10.1016/j.ijpharm.2017.01.050
Abstract: The objective of the present study was to develop a discriminatory and reproducible accelerated release testing method for naltrexone loaded parenteral polymeric microspheres. The commercially available naltrexone microsphere product (Vivitrol®) was used as the testing… read more here.
Keywords: release testing; usp apparatus; naltrexone; method ... See more keywords
Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of substance abuse treatment"
DOI: 10.1016/j.jsat.2017.11.008
Abstract: Extended-release naltrexone (XR-NTX) has several properties that make it an important addition to the pharmacopoeia for addictive disorders. It has no abuse potential, is administeredmonthly and, creating no physiological dependence, has nowithdrawal syndrome on discontinuation.… read more here.
Keywords: oral naltrexone; use; extended release; treatment ... See more keywords
Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of substance abuse treatment"
DOI: 10.1016/j.jsat.2019.05.004
Abstract: Medication-assisted behavior treatment for alcohol use disorder (AUD) holds promise to enhance the efficacy of medication and of behavior therapy when administered individually. The present study examines the treatment benefit of combined outpatient naltrexone (NTX)… read more here.
Keywords: medication; treatment; alcohol; naltrexone ... See more keywords
Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00595
Abstract: Poly(lactide-co-glycolide) (PLGA)-based microparticle formulations have been a mainstay of long-acting injectable drug delivery applications for decades. Despite a long history of use, tools and techniques to analyze and understand these formulations are still under development.… read more here.
Keywords: impact; analysis; release; sequential semisolvent ... See more keywords
Engineered PLGA microspheres for extended-release of naltrexone: in vitro, in vivo, and IVIVR
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutical Development and Technology"
DOI: 10.1080/10837450.2023.2172041
Abstract: Abstract Poly(lactide-co-glycolide) (PLGA)-based formulation is one of the most often used parenteral extended-release forms to deliver various therapeutics. VIVITROL® as a commercialized PLGA microsphere formulation encapsulates naltrexone, a narcotic antagonist for opioid addiction and alcohol… read more here.
Keywords: vivo; plga microspheres; release; extended release ... See more keywords
Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Addiction Medicine"
DOI: 10.1097/adm.0000000000000560
Abstract: CONTEXT To describe the role of opioid antagonist induction in reducing stress response and withdrawal symptoms. OBJECTIVE Complexity of naltrexone induction is limiting broader applicability of opioid antagonist-assisted abstinence. The aim of this clinical trial… read more here.
Keywords: dose; antagonist induction; opioid antagonist; induction ... See more keywords